Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Erba

Showing results (151-160 of 162) with videos related to

Pageof 17
Sort By:
JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
JCO Oncology Practice|March 20, 2025
Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Leukemia|May 11, 2019
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR studyCelalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
The New England Journal of Medicine|June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
The New England Journal of Medicine|July 24, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsMark R Litzow, Zhuoxin Sun, Ryan J Mattison, et al.
Pageof 17

Showing results (151-160 of 162) with videos related to

Sort By:
Pageof 17
JCO Oncology Practice|February 13, 2020
Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
JCO Oncology Practice|March 20, 2025
Erratum: Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients With Acute Myeloid LeukemiaJohn M Pagel, Megan Othus, Guillermo Garcia-Manero, et al.
The Lancet. Oncology|October 3, 2024
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trialEunice S Wang, Ghayas C Issa, Harry P Erba, et al.
Blood|December 17, 2019
Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemiaGail J Roboz, Courtney D DiNardo, Eytan M Stein, et al.
Leukemia|May 11, 2019
Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR studyCelalettin Ustun, Jennifer Le-Rademacher, Hai-Lin Wang, et al.
The Lancet. Oncology|August 4, 2015
Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 studyFarhad Ravandi, Ellen K Ritchie, Hamid Sayar, et al.
Blood|June 2, 2026
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemiaEunice S Wang, Harry P Erba, Amer M Zeidan, et al.
The New England Journal of Medicine|June 5, 2018
Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AMLCourtney D DiNardo, Eytan M Stein, Stéphane de Botton, et al.
Blood|September 15, 2020
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemiaGeoffrey L Uy, Ibrahim Aldoss, Matthew C Foster, et al.
The New England Journal of Medicine|July 24, 2024
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in AdultsMark R Litzow, Zhuoxin Sun, Ryan J Mattison, et al.
Pageof 17